KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBT Margin (2016 - 2025)

Pacific Biosciences Of California has reported EBT Margin over the past 16 years, most recently at 89.97% for Q4 2025.

  • Quarterly results put EBT Margin at 89.97% for Q4 2025, down 9682.0% from a year ago — trailing twelve months through Dec 2025 was 341.28% (down 14030.0% YoY), and the annual figure for FY2025 was 341.28%, down 14030.0%.
  • EBT Margin for Q4 2025 was 89.97% at Pacific Biosciences Of California, up from 97.86% in the prior quarter.
  • Over the last five years, EBT Margin for PACB hit a ceiling of 6.85% in Q4 2024 and a floor of 1147.62% in Q1 2025.
  • Median EBT Margin over the past 5 years was 151.94% (2024), compared with a mean of 229.61%.
  • Peak annual rise in EBT Margin hit 37591bps in 2025, while the deepest fall reached -94619bps in 2025.
  • Pacific Biosciences Of California's EBT Margin stood at 189.22% in 2021, then tumbled by -63bps to 308.5% in 2022, then soared by 54bps to 141.78% in 2023, then soared by 105bps to 6.85% in 2024, then crashed by -1413bps to 89.97% in 2025.
  • The last three reported values for EBT Margin were 89.97% (Q4 2025), 97.86% (Q3 2025), and 105.35% (Q2 2025) per Business Quant data.